Arresto Biosciences

Arresto Biosciences Inc. is a clinical stage platform technology company that develops allosteric inhibitors of matrix enzymes that are involved in the pathogenesis of cancer, fibrosis and inflammatory diseases.  The lead clinical stage product is a monoclonal antibody which has shown efficacy in cancer and fibrosis models, including lung fibrosis.   The company is also developing allosteric inhibitors for the treatment of inflammatory and musculoskeletal diseases.